研究单位：[1]Huashan Hospital[2]China Alliance for Rare Diseases[3]National Center for Neurological Disorders (China)[4]China myasthenia gravis collaborating group (CMGCG)[5]Beijing Hospital,Beijing,Beijing,China,100051[6]Xuanwu hospital, Capital medical university,Beijing,Beijing,China,100053[7]Peking Union Medical College Hospital,Beijing,Beijing,China,100730[8]The First Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China,401147[9]The First Affiliated Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China,510060[10]The Third Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China,510060[11]First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[12]Xiangya hospital, Central south university,Changsha,Hunan,China,410001[13]The First Hospital, Soochow University,Suzhou,Jiangsu,China,215005[14]Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu,China,221004[15]The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330209[16]The First Hospital, Jilin University,Changchun,Jilin,China,130021[17]Huashan Hospital, Fudan University,Shanghai,Shanghai,China,200040[18]Tangdu Hospital, The Air Force Medical University,Xi''an,Shanxi,China,710000[19]West China Hospital, Sichuan University,Chengdu,Sichuan,China,610041[20]Tianjin Medical University General Hospital,Tianjin,Tianjin,China,300052
Myasthenia gravis (MG) is an autoimmune disease caused by dysfunction at the neuromuscular junction, characterized by partial or generalized skeletal muscle weakness and fatigability. The estimated annual incidence rate of MG in China is 0.68/100,000, with a high rate of relapse and poor treatment compliance. This study is a prospective, observational, multi-center patient registry across China. To support standardized management and follow-up of MG patients in China, a Cloud-based MG Patient Management Platform (CN MG Base) was established in September 2023 with the support of the Chinese Rare Diseases Alliance. The platform aims to collect longitudinal clinical data including demographic information, age of onset, medical history, comorbidities, medication usage, treatment responses, and others. It is intended to collect newly registered MG cases each year and follow up with these patients at one-year intervals for ten years
